Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock
Press Release – New York, NY – December 6, 2019 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical stage company developing depression and central nervous system disease therapies, in the successful completion of an underwritten public offering of three million shares of Relmada common stock at a price of $30.00 per share.
The underwriters exercised their over-allotment option for an additional 450,000 shares, bringing gross proceeds to $115 million before the deduction of underwriting discounts, commissions, and other estimated offering expenses. Jefferies, SVB Leerink, and Guggenheim Securities are joint book running managers for the offering.
Relmada intends to use the net proceeds to fund research and development for clinical stage programs related to its lead product candidate, REL-1017 (d-methadone), an oral agent for depression which recently produced favorable results in clinical trials.
Sichenzia Ross Ference LLP also represented Relmada in the listing of its Common Stock on the Nasdaq Capital Market, which commenced trading on October 10, 2019. The firm joined Relmada and its executive leadership at its Nasdaq Bell Ringing Ceremony on October 17.
The Sichenzia Ross Ference LLP team was led by Partners Gregory Sichenzia, Marcelle Balcombe, Barrett DiPaolo, Thomas Rose and Associate Grant Levine.